Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Sanofi
Deal Size : $505.5 million
Deal Type : Licensing Agreement
C4X Discovery Receives Latest Milestone Payment from Sanofi
Details : Under the licensing agreement, Sanofi is seeking to develop and commercialise an oral therapy for the treatment of inflammatory diseases such as psoriasis, psoriatic arthritis etc.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $8.3 million
May 27, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Sanofi
Deal Size : $505.5 million
Deal Type : Licensing Agreement
Lead Product(s) : MB272
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The company’s lead program, MB272, targets the immune receptor B- and T-lymphocyte attenuator and advance pipeline of checkpoint agonist antibodies designed to treat autoimmune disease.
Product Name : MB272
Product Type : Antibody
Upfront Cash : Inapplicable
August 03, 2022
Lead Product(s) : MB272
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Infliximab
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : SGS Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
SGS’s Quay Pharma Collaborates to Develop New Oral Medicine for Inflammatory Bowel Disease
Details : Formulating infliximab as an oral capsule – which must survive the digestive system's harsh environment and reach the colon intact – is transformational.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
July 18, 2022
Lead Product(s) : Infliximab
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : SGS Life Sciences
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : SDC-1802
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US Patent Formally Granted for Sareum’s SDC-1802 TYK2/JAK1 Inhibitor
Details : The United States Patent and Trademark Office has now formally approved its patent application (US Patent Application no. 16/351,620), in respect of an invention associated with Sareum’s proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme.
Product Name : SDC-1802
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 01, 2021
Lead Product(s) : SDC-1802
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Patient Square Capital
Deal Size : $145.0 million
Deal Type : Financing
Details : Proceeds from the investment will support advancement of Apollo's robust pipeline into development, expansion of the company's operations including establishment of a presence in the Boston, MA area and pursuit of new collaborations globally.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 17, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Patient Square Capital
Deal Size : $145.0 million
Deal Type : Financing
Lead Product(s) : SDC-1802
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The authors concluded that an approach using selective TYK2/JAK1 inhibitors may lead to the development of a therapy for lupus that does not involve the harmful side effects of systemic immune system suppression and may benefit numerous lupus patients in...
Product Name : SDC-1802
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 24, 2020
Lead Product(s) : SDC-1802
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable